Substance / Medication

Acalabrutinib

Overview

Active Ingredient
acalabrutinib
RxNorm CUI
1986808
Labeler: AstraZeneca Pharmaceuticals LPUpdated: 2025-01-16T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

None.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
1
Recruiting
1
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Meta-analysis of the efficacy and adverse effects of acalabrutinib in the management of relapsed/refractory chronic lymphocytic leukemia.
Park Daniel, Chan-Golston Alec M, Yan Yueqi et al. · J Chemother · 2025
PMID: 38803142Meta-Analysis
Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalization.
Scheinberg Phillip, Khoshnevis Matt R, Robinson Philip A et al. · Immunohorizons · 2025
PMID: 40461100RCTFull text (PMC)
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia.
Brown Jennifer R, Seymour John F, Jurczak Wojciech et al. · N Engl J Med · 2025
PMID: 39976417RCT
Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma.
Wang Michael, Salek David, Belada David et al. · J Clin Oncol · 2025
PMID: 40311141RCTFull text (PMC)
Real-world efficacy and safety outcomes of acalabrutinib in chronic lymphocytic leukemia: primary results of a French multicentre observational study (NAOS).
Quinquenel Anne, Leprêtre Stéphane, Dilhuydy Marie Sarah et al. · Ann Hematol · 2025
PMID: 40736551ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Acalabrutinib (substance)
SNOMED CT
763037006
UMLS CUI
C4078312
RxNorm CUI
1986808
Labeler
AstraZeneca Pharmaceuticals LP

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.